Page 99 - 202008

Clinical Observation of Recombinant Human Interferon Gel Combined with Baofukang Suppository in the
Treatment of Cervical High-risk HPV Infection
1
4
2
1
3
SU Xiaoyu ，MENG Liping ，ZOU Congcong ，ZHOU Jufeng ，WANG Fang ，CHEN Manling（1. Dept. of
2
Gynaecology，the First Affiliated Hospital of Hainan Medical University，Haikou 570102，China；2. Nursing
Department，the First Affiliated Hospital of Hainan Medical University，Haikou 570102，China；3. Nutritional
Department，the First Affiliated Hospital of Hainan Medical University，Haikou 570102，China；4. Dept. of
Gynaecology，Haikou Municipal People’s Hospital，Haikou 570208，China）
ABSTRACT OBJECTIVE：To investigate therapeutic efficacy and safety of recombinant human interferon gel combined with
Baofukang suppository in the treatment of cervical high-risk human papillomavirus （HPV） infection. METHODS：Totally 259
patients with persistent high-risk HPV infection diagnosed and treated in gynecology department of the First Affiliated Hospital of
Hainan Medical University from Aug. 2017 to Sept. 2019 were selected and divided into interferon group（n＝82），Baofukang
suppository group（n＝86）and combination group（n＝91）according to random number table. The patients in interferon group and
Baofukang suppository group were given Recombinant human interferon α2b gel 1 g, qd or Baofukang suppository 1 capsule，qd；
the patients in combination group were given Recombinant human interferon α2b gel and Baofukang suppository 1 capsule，qd；for
3 months. Then the clinical efficacy， negative time of HPV， duration of abnormal secretion， LCT test results， cervical
inflammation score，HPV relative light unit/critical value（RLU/CO）and the incidence of ADR were recorded. RESULTS：The
total effective rate of combination group was significantly higher than that of interferon group and Baofukang suppository group，
the negative time of HPV and duration of abnormal secretion in combination group were significantly shorter than interferon group
and Baofukang suppository group（P＜0.05）. Before treatment，the normal rate of LCT of 3 groups were 0，and there was no
statistical significance in cervical inflammation score and HPV RLU/CO among 3 groups（P＞0.05）. After treatment，normal rate
of LCT was increased in 3 groups，compared with before treatment（P＜0.05），and normal rate of LCT in combination group was
significantly higher than interferon group and Baofukang suppository group. The cervical inflammation score and HPV RLU/CO
were significantly lower than before treatment，and the combination group was significantly lower than interferon group and
Baofukang suppository group（P＜0.05）. There was no statistical significance in above indicatora after treatment betwent interferon
group and Baofukang suppository group and the incidence of ADR among 3 groups during medication （P＞0.05）.
CONCLUSIONS：The application of recombinant human interferon gel combined with Baofukang suppository is effective and safe
way in the treatment of cervical high-risk HPV infection.
KEYWORDS Recombinant human interferon；Baofukang suppository；Cervix；High-risk HPV；Infection；Clinical observation

人乳头瘤病毒（Human papillomavirus，HPV）是一种 1 资料与方法
[1]
以性传播方式感染皮肤及黏膜的 DNA 病毒 。调查显 1.1 纳入与排除标准
[2]
示，至少80％的性活跃女性有HPV感染史 。HPV感染 纳入标准：（1）宫颈组织病理活检及临床症状确诊
引起的临床症状多样，其中高危型HPV感染与多种恶性 为高危型HPV慢性感染；（2）年龄20～60岁；（3）HPV持
肿瘤的发生关系密切 。宫颈癌是发病率最高的女性生 续感染 12 个月及以上；（4）经液基薄层细胞学检查
[2]
殖系统恶性肿瘤之一，其发病率和病死率居高不下，且
（LCT）可观察到不典型鳞状细胞（ASC）、低度鳞状上皮
易发年龄趋于年轻化，严重影响女性患者的生命健康。 [7]
内病变（LSIL）或炎症反应 。
研究证明，高危型 HPV 感染是宫颈癌的独立危险因素，
排除标准：（1）合并生殖系统恶性肿瘤者；（2）妊娠
[3]
90％以上的宫颈癌患者检出有高危型 HPV 感染 。因
期或哺乳期患者；（3）对本研究所用药物过敏，或已知对
此，探讨治疗高危型HPV感染的有效方法对预防宫颈癌
3 种及以上食物、药物过敏者；（4）合并心、肝、肾等重要
有重要意义。重组人干扰素是一种广谱抗病毒药，能抑
[8]
脏器严重功能不全者 。
制病毒遗传物质的复制，同时提高患者免疫力，已有研
1.2 研究对象
究显示其对HPV持续阳性的患者疗效显著 [4-5] 。保妇康
栓是一种中药制剂，具有生肌止痛、行气破瘀的作用，现 选取 2017 年 8 月－2019 年 9 月于我院妇科确诊的
代药理学研究证明，其具有抗病毒、抗细菌等作用 ，但 高危型 HPV 持续感染患者 259 例。按照随机数字表法
[6]
其在高危型HPV患者中的疗效尚不完全明确。基于此， 将 259 例患者分为干扰素组（n＝82）、保妇康栓组（n＝
本研究选择海南医学院第一附属医院（以下简称“我 86）及联合组（n＝91）。3 组患者的平均年龄及病程比
院”）收治的 259 例高危型 HPV 感染患者采用重组人干 较，差异均无统计学意义（P＞0.05），具有可比性，详见
扰素和保妇康栓单用或联用治疗，观察其对宫颈高危型 表1。本研究试验内容及流程符合医院医学伦理委员会
HPV感染的疗效，旨在为临床治疗提供参考。 相关标准，并获得批准；所有受试者对本研究充分知情

中国药房 2020年第31卷第8期 China Pharmacy 2020 Vol. 31 No. 8 ·985 ·